AR004752A1 - 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion. - Google Patents

2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.

Info

Publication number
AR004752A1
AR004752A1 ARP960105319A ARP960105319A AR004752A1 AR 004752 A1 AR004752 A1 AR 004752A1 AR P960105319 A ARP960105319 A AR P960105319A AR P960105319 A ARP960105319 A AR P960105319A AR 004752 A1 AR004752 A1 AR 004752A1
Authority
AR
Argentina
Prior art keywords
methyl
preparation
purin
imidazo
cyclopentane
Prior art date
Application number
ARP960105319A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR004752A1 publication Critical patent/AR004752A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de 2-[[4-halo-[1,1-bifenil]4-il]metil-5-metilespiro[ ciclopentano-1,7(8h)-[3h imidazo[2,1-b)purin]-4(5h)-onas, útiles comoantihipertensivos y broncodilatores de lafórmula (I) o su sal farmacéuticamente aceptable donde X es fluoro,cloro o bromo. Dichos compuestos seusan para lapreparación de un medicamento, además se describe una composición farmacéutica y el lproceso para su preparación.
ARP960105319A 1995-11-28 1996-11-25 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion. AR004752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56371795A 1995-11-28 1995-11-28

Publications (1)

Publication Number Publication Date
AR004752A1 true AR004752A1 (es) 1999-03-10

Family

ID=24251614

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105319A AR004752A1 (es) 1995-11-28 1996-11-25 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.

Country Status (8)

Country Link
EP (1) EP0863902A1 (es)
JP (1) JP2000501095A (es)
AR (1) AR004752A1 (es)
AU (1) AU1055597A (es)
CA (1) CA2237956A1 (es)
CO (1) CO4480029A1 (es)
WO (1) WO1997019947A1 (es)
ZA (1) ZA969888B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
JP2003519153A (ja) 1999-12-24 2003-06-17 バイエル アクチェンゲゼルシャフト イソオキサゾロピリミジノン類及びその使用
EP1261609B1 (de) 1999-12-24 2004-11-03 Bayer HealthCare AG Triazolotriazinone und ihre verwendung
US6803365B2 (en) 1999-12-24 2004-10-12 Bayer Aktlengesellschaft Imidazo[1,3,5]triazinones and the use thereof
EP3562828A1 (en) 2016-12-28 2019-11-06 Dart NeuroScience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
US11434247B1 (en) 2017-11-27 2022-09-06 Dart Neuroscience Llc Substituted furanopyrimidine compounds as PDE1 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238609A (en) * 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
EP0686157A1 (en) * 1993-02-26 1995-12-13 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them

Also Published As

Publication number Publication date
ZA969888B (en) 1997-05-26
JP2000501095A (ja) 2000-02-02
MX9804198A (es) 1998-10-31
WO1997019947A1 (en) 1997-06-05
CO4480029A1 (es) 1997-07-09
AU1055597A (en) 1997-06-19
CA2237956A1 (en) 1997-06-05
EP0863902A1 (en) 1998-09-16

Similar Documents

Publication Publication Date Title
AU3959693A (en) Alpha-aminoboronic acid peptides and their use as elastase inhibitors
GB9216272D0 (en) Substituted heterocycles
IL109526A0 (en) Benzofuranyl- and thiophenyl-alkanecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
FI944802A (fi) HLE-proteiinien aktiivisuutta inhiboivat laktaamidipeptidit
FI944823A (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
AR004752A1 (es) 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.
HUT38097A (en) Process for preparing substituted benzopyrans and pharmaceutical compositions containing them as active substances
FI945696A (fi) Laktaamidipeptidejä, joilla on HLE:a inhiboiva aktiivisuus
FI946202A0 (fi) Fluoria sisältäviä dipeptidejä inhibiittoreina ihmisen lenkosyyttielastaasi-inhibiittoreita vastaan
DE3070847D1 (en) Benzazepine derivatives, process and intermediates for their preparation, their use and pharmaceutical compositions containing them
HUP9800512A2 (hu) Moenomicin csoportba tartozó antibiotikumok bizmutsói, eljárás előállításukra, ezek alkalmazása és ezeket tartalmazó gyógyszerkészítmények
TH23729A (th) พิร์โรลิลเททระไฮโดรเบนโซควินอกแซลีนไดโอน การเตรียมและการใช้สารเหล่านั้น
TH24203A (th) อนุพันธ์ของออพทิคัลลี แอคทีฟ เบนโซไชอีพิน การเตรียมและการใช้ประโยชน์ของสารเหล่านี้